Sutro is advancing a next-generation antibody-drug conjugate platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer.

Sutro’s proprietary technology enables therapeutics that may provide broader patient benefit and an improved patient experience.